Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 4/2015

01.10.2015 | Review

Safety of insulin analogs during pregnancy: a meta-analysis

verfasst von: ShiShi Lv, JiYing Wang, Yong Xu

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of this study was to assess the safety of four insulin analogs (aspart, lispro, glargine, and detemir) for the treatment of diabetes in pregnancy.

Methods

We searched Embase, Pubmed, and the Cochrane Central Register for Controlled Trials database through May 31, 2014. All articles were reviewed by two independent researchers, and if a discrepancy was noted, a third researcher was consulted. Results data were summarized by RevMan 5.2 software.

Results

Our search resulted in the retrieval and screening of 3519 studies. Of those, 24 studies met the eligibility criteria; the studies reported on a total of 3734 women with pre-gestational or gestational diabetes during pregnancy. The use of lispro was associated with lower rates of neonatal jaundice (RR = 0.63) and severe maternal hypoglycemia (RR = 0.33) than regular insulin. Lispro use was also associated with higher birth weight (WMD = 116.44) and an increased incidence of large for gestational age (LGA) births (RR = 1.42) compared with regular insulin. Rates of cesarean section and macrosomia were similar in pregnant women treated with aspart and regular insulin. Birth weights and rates of severe maternal hypoglycemia, respiratory dysfunction syndrome, and neonatal intensive care unit admission were similar after pregnant women were treated with glargine and NPH insulin. Rates of LGA, macrosomia, and neonatal hypoglycemia were similar after pregnant women were treated with detemir and NPH insulin.

Conclusions

Aspart, glargine, and detemir are safe treatment options for diabetes during pregnancy; these insulin analogs did not increase complications for the mothers or fetuses in our study. However, lispro was related to higher birth weight and increased rate of LGA in neonates. More high-quality randomized controlled trials are needed to clarify the best treatment options for diabetes during pregnancy.
Literatur
1.
Zurück zum Zitat Lawrence JM, Contreras R, Chen W et al (2008) Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 31:899–904CrossRefPubMed Lawrence JM, Contreras R, Chen W et al (2008) Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 31:899–904CrossRefPubMed
2.
Zurück zum Zitat DeSisto CL, Kim SY, Charma AJ (2014) Prevalence estimates of gestational diabetesmellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007–2010. Prev Chronic Dis 19(11):E104 DeSisto CL, Kim SY, Charma AJ (2014) Prevalence estimates of gestational diabetesmellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007–2010. Prev Chronic Dis 19(11):E104
3.
Zurück zum Zitat HAPO Study Cooperative Research Group, Metaqer BE, Lowe LP et al (2008) Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358:1991–2002CrossRef HAPO Study Cooperative Research Group, Metaqer BE, Lowe LP et al (2008) Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358:1991–2002CrossRef
4.
Zurück zum Zitat Edson EJ, Bracco OL, Vambergue A et al (2010) Managing diabetes during pregnancy with insulin lispro:a safe alternative to human insulin. Endocr Pract 16:1020–1027CrossRefPubMed Edson EJ, Bracco OL, Vambergue A et al (2010) Managing diabetes during pregnancy with insulin lispro:a safe alternative to human insulin. Endocr Pract 16:1020–1027CrossRefPubMed
5.
Zurück zum Zitat Lapolla A, Dalfra MG, Spezia R et al (2008) Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol 45:61–66CrossRefPubMed Lapolla A, Dalfra MG, Spezia R et al (2008) Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol 45:61–66CrossRefPubMed
6.
Zurück zum Zitat Durnwald CP, Landon MB (2008) A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy. J Matern Fetal Neonatal Med 21:309–313CrossRefPubMed Durnwald CP, Landon MB (2008) A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy. J Matern Fetal Neonatal Med 21:309–313CrossRefPubMed
7.
Zurück zum Zitat Banerjee M, Bhattacharya A, Hughes SM et al (2009) Efficacy of insulin lispro in pregnancies complicated with pregestational diabetes mellitus. Pract Diabetes Int 26:366–370CrossRef Banerjee M, Bhattacharya A, Hughes SM et al (2009) Efficacy of insulin lispro in pregnancies complicated with pregestational diabetes mellitus. Pract Diabetes Int 26:366–370CrossRef
8.
Zurück zum Zitat Aydin Y, Berker D, Direktor N et al (2008) Is insulin lispro safe in pregnant women: does it cause any adverse outcomes on infants or mothers? Diabetes Res Clin Pract 80(44):4–448 Aydin Y, Berker D, Direktor N et al (2008) Is insulin lispro safe in pregnant women: does it cause any adverse outcomes on infants or mothers? Diabetes Res Clin Pract 80(44):4–448
9.
Zurück zum Zitat García-Domínguez M, Herranz L, Hillman N et al (2011) Use of insulin lispro during pregnancy in women with pregestational diabetes mellitus. Med Clin 137:581–586CrossRef García-Domínguez M, Herranz L, Hillman N et al (2011) Use of insulin lispro during pregnancy in women with pregestational diabetes mellitus. Med Clin 137:581–586CrossRef
10.
Zurück zum Zitat Cypryk K, Sobczak M, Pertyńska-Marczewska M et al (2004) Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Med Sci Monit 10:PI29–PI32PubMed Cypryk K, Sobczak M, Pertyńska-Marczewska M et al (2004) Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Med Sci Monit 10:PI29–PI32PubMed
11.
Zurück zum Zitat Evers IM, de Valk HW, Mol BW et al (2002) Macrosomia despite good glycaemic control in type1 diabetic pregnancy results of a nationalwide study in the Netherlands. Diabetologia 45:1484–1489CrossRefPubMed Evers IM, de Valk HW, Mol BW et al (2002) Macrosomia despite good glycaemic control in type1 diabetic pregnancy results of a nationalwide study in the Netherlands. Diabetologia 45:1484–1489CrossRefPubMed
12.
Zurück zum Zitat Colatrella A, Visalli N, Abbruzzese S et al (2013) Comparison of insulin lispro protamine suspension with NPH insulin in pregnant women with type 2 and gestational diabetes mellitus: maternal and perinatal outcomes. Int J Endocrinol 2013:151975PubMedCentralCrossRefPubMed Colatrella A, Visalli N, Abbruzzese S et al (2013) Comparison of insulin lispro protamine suspension with NPH insulin in pregnant women with type 2 and gestational diabetes mellitus: maternal and perinatal outcomes. Int J Endocrinol 2013:151975PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Balaji V, Balaji MS, Alexander C et al (2012) Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study. Gynecol Endocrinol 28:529–532CrossRefPubMed Balaji V, Balaji MS, Alexander C et al (2012) Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study. Gynecol Endocrinol 28:529–532CrossRefPubMed
14.
Zurück zum Zitat Balaji V, Balaji MS, Alexander C et al (2010) Premixed insulin aspart 30 (Bia sp 30) vs premixed human insulin 30 (Bhi 30) in gestational diabetes mellitus—a pilot study. J Assoc Physician India 58:99–101 Balaji V, Balaji MS, Alexander C et al (2010) Premixed insulin aspart 30 (Bia sp 30) vs premixed human insulin 30 (Bhi 30) in gestational diabetes mellitus—a pilot study. J Assoc Physician India 58:99–101
15.
Zurück zum Zitat Hod M, Damm P, Kaaja R et al (2008) Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 198:186.e1–186.e7CrossRef Hod M, Damm P, Kaaja R et al (2008) Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 198:186.e1–186.e7CrossRef
16.
Zurück zum Zitat Poyhonen-Alho M, Ronnemaa T, Saltevo J et al (2007) Use of insulin glargine during pregnancy. Acta Obstetricia et Gynecologica 86:1171–1174CrossRef Poyhonen-Alho M, Ronnemaa T, Saltevo J et al (2007) Use of insulin glargine during pregnancy. Acta Obstetricia et Gynecologica 86:1171–1174CrossRef
17.
Zurück zum Zitat Fang YM, MacKeen D, Egan JF et al (2009) Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med 22:249–253CrossRefPubMed Fang YM, MacKeen D, Egan JF et al (2009) Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med 22:249–253CrossRefPubMed
18.
Zurück zum Zitat Egerman RS, Ramsey RD, Kao LW et al (2009) Perinatal outcomes in pregnancies managed with antenatal insulin glargine. Am J Perinatol 26:591–595CrossRefPubMed Egerman RS, Ramsey RD, Kao LW et al (2009) Perinatal outcomes in pregnancies managed with antenatal insulin glargine. Am J Perinatol 26:591–595CrossRefPubMed
19.
Zurück zum Zitat Imbergamo MP, Amato MC, Sciortino G et al (2008) use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther 30:1476–1484CrossRefPubMed Imbergamo MP, Amato MC, Sciortino G et al (2008) use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther 30:1476–1484CrossRefPubMed
20.
Zurück zum Zitat Negrato CA, Rafacho A, Negrato G et al (2010) Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract 89:46–51CrossRefPubMed Negrato CA, Rafacho A, Negrato G et al (2010) Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract 89:46–51CrossRefPubMed
21.
Zurück zum Zitat Price N, Bartlett C, Gillmer M (2007) Use of insulin glargine during pregnancy: a case–control pilot study. BJOG 114:453–457CrossRefPubMed Price N, Bartlett C, Gillmer M (2007) Use of insulin glargine during pregnancy: a case–control pilot study. BJOG 114:453–457CrossRefPubMed
22.
Zurück zum Zitat Smith JG, Manuck TA, White J et al (2009) Insulin glargine versus neutral protamine hagedorn insulin for treatment of diabetes in pregnancy. Am J Perinatol 26:57–62CrossRefPubMed Smith JG, Manuck TA, White J et al (2009) Insulin glargine versus neutral protamine hagedorn insulin for treatment of diabetes in pregnancy. Am J Perinatol 26:57–62CrossRefPubMed
23.
Zurück zum Zitat Imbergamo MP, Amato MC, Amodeo R et al (2012) Use of basal insulin analog detemir in pregnant women with type1 diabetes:a case-control retrospective study. Giorn Ital Ostet Ginecol 34:491–498 Imbergamo MP, Amato MC, Amodeo R et al (2012) Use of basal insulin analog detemir in pregnant women with type1 diabetes:a case-control retrospective study. Giorn Ital Ostet Ginecol 34:491–498
24.
Zurück zum Zitat Hod M, Mathiesen ER, Jovanovic L et al (2014) A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med 27:7–13PubMedCentralCrossRefPubMed Hod M, Mathiesen ER, Jovanovic L et al (2014) A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med 27:7–13PubMedCentralCrossRefPubMed
25.
Zurück zum Zitat Edson EJ, Bracco OL, Vambergue A et al (2010) Managing diabetes during pregnancy with insulin lispro :a safe alternative to human insulin. Endocr Pract 16:1020–1027CrossRefPubMed Edson EJ, Bracco OL, Vambergue A et al (2010) Managing diabetes during pregnancy with insulin lispro :a safe alternative to human insulin. Endocr Pract 16:1020–1027CrossRefPubMed
26.
Zurück zum Zitat Blanco CG, Ballesteros AC, Saladich IG et al (2011) Glycemic control and pregnancy outcomes in women with type 1 Diabetes mellitus using lispro versus regular insulin: a systematic review and meta-analysis. Diabetes Technol Ther 13:907–911CrossRef Blanco CG, Ballesteros AC, Saladich IG et al (2011) Glycemic control and pregnancy outcomes in women with type 1 Diabetes mellitus using lispro versus regular insulin: a systematic review and meta-analysis. Diabetes Technol Ther 13:907–911CrossRef
27.
Zurück zum Zitat Elhddad AS, Lashen H (2013) Fetal growthin relation tomaternal and fetal IGF-axes: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 92:997–1006CrossRefPubMed Elhddad AS, Lashen H (2013) Fetal growthin relation tomaternal and fetal IGF-axes: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 92:997–1006CrossRefPubMed
28.
Zurück zum Zitat Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005CrossRefPubMed Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005CrossRefPubMed
29.
Zurück zum Zitat Wilde MI (1997) Mc Tavish D. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54:597–614CrossRefPubMed Wilde MI (1997) Mc Tavish D. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54:597–614CrossRefPubMed
30.
Zurück zum Zitat Boskovic R, Knie B, Feig DS et al (2003) Transfer of insulin lispro across the human placenta. Diabetes Care 26:1390–1394CrossRefPubMed Boskovic R, Knie B, Feig DS et al (2003) Transfer of insulin lispro across the human placenta. Diabetes Care 26:1390–1394CrossRefPubMed
31.
Zurück zum Zitat The Guideline Development Group (2008) Management of diabetes from preconception to the postnatal period: summary of NICE guidance. BMJ 336:714–717PubMedCentralCrossRef The Guideline Development Group (2008) Management of diabetes from preconception to the postnatal period: summary of NICE guidance. BMJ 336:714–717PubMedCentralCrossRef
32.
Zurück zum Zitat Blumer I, Hadar E, Hadden DR et al (2013) Diabetes and Pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98:4227–4249CrossRefPubMed Blumer I, Hadar E, Hadden DR et al (2013) Diabetes and Pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98:4227–4249CrossRefPubMed
33.
Zurück zum Zitat Pollex E, Moretti ME, Koren G et al (2011) Safety of Insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother 45:9–16CrossRefPubMed Pollex E, Moretti ME, Koren G et al (2011) Safety of Insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother 45:9–16CrossRefPubMed
34.
Zurück zum Zitat Sciacca L, Cassarino MF, Genua M et al (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53:1743–1753CrossRefPubMed Sciacca L, Cassarino MF, Genua M et al (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53:1743–1753CrossRefPubMed
35.
36.
Zurück zum Zitat Callesen NF, Damm J, Mathiesen JM et al (2013) Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes:comparison of glycaemic control and pregnancy outcome. J Mater Fetal Neonatal Med 26:588–592CrossRef Callesen NF, Damm J, Mathiesen JM et al (2013) Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes:comparison of glycaemic control and pregnancy outcome. J Mater Fetal Neonatal Med 26:588–592CrossRef
37.
Zurück zum Zitat Shankardass K, O’campo P, Dodds L et al (2014) Magnitude of income- related disparities in adverse perinatal outcomes. BMC Pregnancy Childbith 14:96CrossRef Shankardass K, O’campo P, Dodds L et al (2014) Magnitude of income- related disparities in adverse perinatal outcomes. BMC Pregnancy Childbith 14:96CrossRef
38.
Zurück zum Zitat Blumenshine P, Egerter S, Barclay CJ et al (2010) Socioeconomic disparities in adverse birth outcomes: a systematic review. Am J Prev Med 39:263–272CrossRefPubMed Blumenshine P, Egerter S, Barclay CJ et al (2010) Socioeconomic disparities in adverse birth outcomes: a systematic review. Am J Prev Med 39:263–272CrossRefPubMed
39.
Zurück zum Zitat Mortense LH (2013) Socioeconomic inequality in birth weight and gestational age in Denmark 1996-2007: using a family-based approach to explore alternative explanations. Soc Sci Med 76:1–7CrossRef Mortense LH (2013) Socioeconomic inequality in birth weight and gestational age in Denmark 1996-2007: using a family-based approach to explore alternative explanations. Soc Sci Med 76:1–7CrossRef
40.
Zurück zum Zitat Scifres CM, Feqhali MN, Althouse AD et al (2014) Effect of excess gestational weight gain on pregnancy outcomes in women with type1 diabetes. Obstet Gynecol 123:1295–1302CrossRefPubMed Scifres CM, Feqhali MN, Althouse AD et al (2014) Effect of excess gestational weight gain on pregnancy outcomes in women with type1 diabetes. Obstet Gynecol 123:1295–1302CrossRefPubMed
Metadaten
Titel
Safety of insulin analogs during pregnancy: a meta-analysis
verfasst von
ShiShi Lv
JiYing Wang
Yong Xu
Publikationsdatum
01.10.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 4/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-015-3692-3

Weitere Artikel der Ausgabe 4/2015

Archives of Gynecology and Obstetrics 4/2015 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.